Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Free webinar: Telepathology: is there added value in LMICs?
Free webinar: Telepathology: is there added value in LMICs?

Front-line combinations in multiple myeloma: Highlights from EHA 2017

Prof Joy Ho and Prof Je-Jung Lee
Front-line combinations in multiple myeloma: Highlights from EHA 2017 ( Prof Joy Ho and Prof Je-Jung Lee )
25 Jun 2017

Latest in relapsed and refractory multiple myeloma

Prof Heinz Ludwig, Prof Wee Joo Chng and Prof James Chim
Latest in relapsed and refractory multiple myeloma ( Prof Heinz Ludwig, Prof Wee Joo Chng and Prof James Chim )
25 Jun 2017

Lenalidomide with CD19 antibodies in L-MIND

Dr Kami Maddocks - Ohio State University, Columbus, USA
Lenalidomide with CD19 antibodies in L-MIND ( Dr Kami Maddocks - Ohio State University, Columbus, USA )
25 Jun 2017

The Myeloma XI trial - lenalidomide or thalidomide in triplet

Dr Charlotte Pawlyn - The Institute of Cancer Research, London, UK
The Myeloma XI trial - lenalidomide or thalidomide in triplet ( Dr Charlotte Pawlyn - The Institute of Cancer Research, London, UK )
25 Jun 2017

Denosumab or zoledronic acid for bone disease in multiple myeloma

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
Denosumab or zoledronic acid for bone disease in multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )
25 Jun 2017

Hemcare - multiple myeloma learning programme

Erik Aerts - President of HNHCP, Winterthur, Switzerland
Hemcare - multiple myeloma learning programme ( Erik Aerts - President of HNHCP, Winterthur, Switzerland )
24 Jun 2017

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM

Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
24 Jun 2017

Enasidenib in mIDH relapsed and refractory AML

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA
Enasidenib in mIDH relapsed and refractory AML ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )
24 Jun 2017

Impact of mutational profile at diagnosis for MDS/CML

Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA
Impact of mutational profile at diagnosis for MDS/CML ( Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017

Delayed infection exposure as a trigger for childhood ALL

Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany
Delayed infection exposure as a trigger for childhood ALL ( Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany )
24 Jun 2017

Triplet therapy for all comers in the CLL-BAG trial

Dr Paula Cramer – University of Cologne, Cologne, Germany
Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )
24 Jun 2017

The role of patient advocates in trial design, participation

Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy
The role of patient advocates in trial design, participation ( Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy )
24 Jun 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation